-
Je něco špatně v tomto záznamu ?
Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide
M. Dawidowski, M. Król, B. Szulczyk, A. Chodkowski, P. Podsadni, P. Konopelski, M. Ufnal, P. Szuberski, MZ. Wróbel, Y. Zhang, A. El Harchi, JC. Hancox, D. Jarkovska, E. Mistrova, J. Sviglerova, M. Štengl, GM. Popowicz, J. Turło
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
PG/12/69/29784
British Heart Foundation - United Kingdom
PG/14/61/31015
British Heart Foundation - United Kingdom
- MeSH
- acetamidy aplikace a dávkování chemie terapeutické užití MeSH
- antikonvulziva aplikace a dávkování chemie terapeutické užití MeSH
- disopyramid aplikace a dávkování chemie terapeutické užití MeSH
- elektrický šok MeSH
- injekce intraperitoneální MeSH
- injekce subkutánní MeSH
- krysa rodu rattus MeSH
- molekulární struktura MeSH
- myši MeSH
- pentylentetrazol aplikace a dávkování MeSH
- potkani Wistar MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- záchvaty chemicky indukované farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012625
- 003
- CZ-PrNML
- 005
- 20210507101700.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bioorg.2020.103717 $2 doi
- 035 __
- $a (PubMed)32171994
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dawidowski, Maciej $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. Electronic address: maciej.dawidowski@wum.edu.pl
- 245 10
- $a Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide / $c M. Dawidowski, M. Król, B. Szulczyk, A. Chodkowski, P. Podsadni, P. Konopelski, M. Ufnal, P. Szuberski, MZ. Wróbel, Y. Zhang, A. El Harchi, JC. Hancox, D. Jarkovska, E. Mistrova, J. Sviglerova, M. Štengl, GM. Popowicz, J. Turło
- 520 9_
- $a A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.
- 650 _2
- $a acetamidy $x aplikace a dávkování $x chemie $x terapeutické užití $7 D000081
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antikonvulziva $x aplikace a dávkování $x chemie $x terapeutické užití $7 D000927
- 650 _2
- $a disopyramid $x aplikace a dávkování $x chemie $x terapeutické užití $7 D004206
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a elektrický šok $7 D004597
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a injekce intraperitoneální $7 D007274
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a pentylentetrazol $x aplikace a dávkování $7 D010433
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a záchvaty $x chemicky indukované $x farmakoterapie $7 D012640
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Król, Marek $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 700 1_
- $a Szulczyk, Bartłomiej $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland; Laboratory of Physiology and Pathophysiology, Centre for Preclinical Research, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland
- 700 1_
- $a Chodkowski, Andrzej $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 700 1_
- $a Podsadni, Piotr $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 700 1_
- $a Konopelski, Piotr $u Department of Experimental Physiology and Pathophysiology, Centre for Preclinical Research, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland
- 700 1_
- $a Ufnal, Marcin $u Department of Experimental Physiology and Pathophysiology, Centre for Preclinical Research, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland
- 700 1_
- $a Szuberski, Piotr $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 700 1_
- $a Wróbel, Martyna Zofia $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 700 1_
- $a Zhang, Yihong $u School of Physiology, Pharmacology and Neuroscience, Faculty of Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom
- 700 1_
- $a El Harchi, Aziza $u School of Physiology, Pharmacology and Neuroscience, Faculty of Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom
- 700 1_
- $a Hancox, Jules C $u School of Physiology, Pharmacology and Neuroscience, Faculty of Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom
- 700 1_
- $a Jarkovska, Dagmar $u Department of Physiology, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Mistrova, Eliska $u Department of Physiology, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Sviglerova, Jitka $u Department of Physiology, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Štengl, Milan $u Department of Physiology, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Popowicz, Grzegorz M $u Institute of Structural Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
- 700 1_
- $a Turło, Jadwiga $u Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- 773 0_
- $w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 98, č. - (2020), s. 103717
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32171994 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101700 $b ABA008
- 999 __
- $a ok $b bmc $g 1650898 $s 1133004
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 98 $c - $d 103717 $e 20200305 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
- GRA __
- $a PG/12/69/29784 $p British Heart Foundation $2 United Kingdom
- GRA __
- $a PG/14/61/31015 $p British Heart Foundation $2 United Kingdom
- LZP __
- $a Pubmed-20210420